الفهرس Only 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
Kidney transplantation is treatment of choice for pediatric end stage renal disease. In this study, Visfatin serum level has been evaluated (in 30 hemodialysis patients, 36 transplant recipients, and 30 controls), as a measure for endothelial dysfunction, and has been compared to brachial artery flow mediated dilatation. Visfatin level in transplant recipients [median (IQR) of 4 (3.5-5.8) ng/ml], was significantly (p<0.0001) lower than the hemodialysis group [median (IQR) of 65 (30-70) ng/ml], and not significantly different from controls [median (IQR) of 5 (2.4-6) ng/ml)]. Flow mediated dilatation was also better in transplant recipients. No direct statistical correlation could be reached between Visfatin level and flow-mediated dilatation. Endothelial dysfunction is significantly improved in transplant recipients